Drug intelligence / Profile preview

methotrexate + actinomycin D

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination chemotherapy regimen consisting of methotrexate and actinomycin D. This combination is primarily used in the treatment of gestational trophoblastic neoplasia (GTN), particularly low-risk GTN. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate and interfering with DNA synthesis. Actinomycin D is an antibiotic that binds to DNA and inhibits RNA synthesis. Together, these agents provide enhanced efficacy compared to either agent alone in treating GTN.

Targets

DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on methotrexate + actinomycin D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + actinomycin D.

Explore the full profile